William Bremer1, Heather Blasczyk1, Xin Yin1, Eduardo Salinas2, Arash Grakoui2, Zongdi Feng3, Christopher Walker4. 1. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's, 700 Children's Drive, Columbus, OH, USA. 2. Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA. 3. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's, 700 Children's Drive, Columbus, OH, USA; Division of Microbiology and Immunology, Emory Vaccine Center and Emory University School of Medicine, Atlanta, GA, USA. 4. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's, 700 Children's Drive, Columbus, OH, USA; Division of Microbiology and Immunology, Emory Vaccine Center and Emory University School of Medicine, Atlanta, GA, USA. Electronic address: christopher.walker@nationwidechildrens.org.
Abstract
BACKGROUND & AIMS: HEV is a significant cause of acute hepatitis globally. Some genotypes establish persistent infection when immunity is impaired. Adaptive immune mechanisms that mediate resolution of infection have not been identified. Herein, the requirement for CD8+ T cells to control HEV infection was assessed in rhesus macaques, a model of acute and persistent HEV infection in humans. METHODS: Rhesus macaques were untreated or treated with depleting anti-CD8α monoclonal antibodies before challenge with an HEV genotype (gt)3 isolate derived from a chronically infected human patient. HEV replication, alanine aminotransferase, anti-capsid antibody and HEV-specific CD4+ and CD8+ T cell responses were assessed after infection. RESULTS: HEV control in untreated macaques coincided with the onset of a neutralizing IgG response against the ORF2 capsid and liver infiltration of functional HEV-specific CD4+ and CD8+ T cells. Virus control was delayed by 1 week in CD8+ T cell-depleted macaques. Infection resolved with onset of a neutralizing IgG antibody response and a much more robust expansion of CD4+ T cells with antiviral effector function. CONCLUSIONS: Liver infiltration of functional CD8+ T cells coincident with HEV clearance in untreated rhesus macaques, and a 1-week delay in HEV clearance in CD8+ T cell-depleted rhesus macaques, support a role for this subset in timely control of virus replication. Resolution of infection in the absence of CD8+ T cells nonetheless indicates that neutralizing antibodies and/or CD4+ T cells may act autonomously to inhibit HEV replication. HEV susceptibility to multiple adaptive effector mechanisms may explain why persistence occurs only with generalized immune suppression. The findings also suggest that neutralizing antibodies and/or CD4+ T cells should be considered as a component of immunotherapy for chronic infection. LAY SUMMARY: The hepatitis E virus (HEV) is a major cause of liver disease globally. Some genetic types (genotypes) of HEV persist in the body if immunity is impaired. Our objective was to identify immune responses that promote clearance of HEV. Findings indicate that HEV may be susceptible to multiple arms of the immune response that can act independently to terminate infection. They also provide a pathway to assess immune therapies for chronic HEV infection.
BACKGROUND & AIMS: HEV is a significant cause of acute hepatitis globally. Some genotypes establish persistent infection when immunity is impaired. Adaptive immune mechanisms that mediate resolution of infection have not been identified. Herein, the requirement for CD8+ T cells to control HEV infection was assessed in rhesus macaques, a model of acute and persistent HEV infection in humans. METHODS: Rhesus macaques were untreated or treated with depleting anti-CD8α monoclonal antibodies before challenge with an HEV genotype (gt)3 isolate derived from a chronically infected human patient. HEV replication, alanine aminotransferase, anti-capsid antibody and HEV-specific CD4+ and CD8+ T cell responses were assessed after infection. RESULTS: HEV control in untreated macaques coincided with the onset of a neutralizing IgG response against the ORF2 capsid and liver infiltration of functional HEV-specific CD4+ and CD8+ T cells. Virus control was delayed by 1 week in CD8+ T cell-depleted macaques. Infection resolved with onset of a neutralizing IgG antibody response and a much more robust expansion of CD4+ T cells with antiviral effector function. CONCLUSIONS: Liver infiltration of functional CD8+ T cells coincident with HEV clearance in untreated rhesus macaques, and a 1-week delay in HEV clearance in CD8+ T cell-depleted rhesus macaques, support a role for this subset in timely control of virus replication. Resolution of infection in the absence of CD8+ T cells nonetheless indicates that neutralizing antibodies and/or CD4+ T cells may act autonomously to inhibit HEV replication. HEV susceptibility to multiple adaptive effector mechanisms may explain why persistence occurs only with generalized immune suppression. The findings also suggest that neutralizing antibodies and/or CD4+ T cells should be considered as a component of immunotherapy for chronic infection. LAY SUMMARY: The hepatitis E virus (HEV) is a major cause of liver disease globally. Some genetic types (genotypes) of HEV persist in the body if immunity is impaired. Our objective was to identify immune responses that promote clearance of HEV. Findings indicate that HEV may be susceptible to multiple arms of the immune response that can act independently to terminate infection. They also provide a pathway to assess immune therapies for chronic HEV infection.
Authors: Patrick Behrendt; Birgit Bremer; Daniel Todt; Richard J P Brown; Albert Heim; Michael P Manns; Eike Steinmann; Heiner Wedemeyer Journal: J Infect Dis Date: 2016-05-27 Impact factor: 5.226
Authors: Patrick Behrendt; Stefan Lüth; Werner Dammermann; Svenja Drave; Richard J P Brown; Daniel Todt; Ulrike Schnoor; Eike Steinmann; Heiner Wedemeyer; Sven Pischke; Christof Iking-Konert Journal: Joint Bone Spine Date: 2016-11-08 Impact factor: 4.929
Authors: Zongdi Feng; Lucinda Hensley; Kevin L McKnight; Fengyu Hu; Victoria Madden; Lifang Ping; Sook-Hyang Jeong; Christopher Walker; Robert E Lanford; Stanley M Lemon Journal: Nature Date: 2013-03-31 Impact factor: 49.962
Authors: Anthony Brown; John S Halliday; Leo Swadling; Richie G Madden; Richard Bendall; Jeremy G Hunter; James Maggs; Peter Simmonds; Donald B Smith; Louisa Vine; Cara McLaughlin; Jane Collier; David Bonsall; Katie Jeffery; Susanna Dunachie; Paul Klenerman; Jacques Izopet; Nassim Kamar; Harry R Dalton; Eleanor Barnes Journal: Hepatology Date: 2016-10-28 Impact factor: 17.425